• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    5/6/24 4:31:06 PM ET
    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATPC alert in real time by email

    Gainers

    • Agape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday's after-market session. The market value of their outstanding shares is at $24.9 million.
    • FibroGen (NASDAQ:FGEN) shares increased by 20.68% to $1.4. The market value of their outstanding shares is at $139.2 million. As per the news, the Q1 earnings report came out today.
    • RxSight (NASDAQ:RXST) shares rose 11.39% to $70.0. The company's market cap stands at $2.6 billion. As per the news, the Q1 earnings report came out today.
    • Innovative Eyewear (NASDAQ:LUCY) shares increased by 10.81% to $0.25. The market value of their outstanding shares is at $3.2 million.
    • Hims & Hers Health (NYSE:HIMS) shares increased by 10.72% to $12.9. The company's market cap stands at $2.7 billion. As per the press release, Q1 earnings came out today.
    • iSpecimen (NASDAQ:ISPC) stock increased by 8.58% to $0.3. The company's market cap stands at $2.7 million.

    Losers

    • Predictive Oncology (NASDAQ:POAI) shares decreased by 9.1% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $6.5 million.
    • SI-BONE (NASDAQ:SIBN) shares fell 6.77% to $13.5. The company's market cap stands at $556.2 million. As per the news, the Q1 earnings report came out today.
    • Anitra (AMEX:AZTR) stock fell 5.68% to $0.25. The company's market cap stands at $7.2 million.
    • Ontrak (NASDAQ:OTRK) stock declined by 5.28% to $0.24. The market value of their outstanding shares is at $11.2 million.
    • Clene (NASDAQ:CLNN) shares declined by 5.15% to $0.4. The company's market cap stands at $51.6 million.
    • Regulus Therapeutics (NASDAQ:RGLS) shares fell 4.96% to $2.3. The market value of their outstanding shares is at $150.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC
    $AZTR
    $CLNN
    $FGEN

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    RxSight Inc.
    $RXST
    1/30/2026Mkt Perform
    William Blair
    SI-BONE Inc.
    $SIBN
    1/27/2026$21.00Buy
    TD Cowen
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ugwumba Chidozie

    4 - Clene Inc. (0001822791) (Issuer)

    3/26/26 5:39:47 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Okupe Oluyemi

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/24/26 6:09:57 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Salva Francisco D.

    4 - Azitra, Inc. (0001701478) (Issuer)

    3/20/26 4:30:30 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers

    Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Hims & Hers Health, Inc. (NYSE:HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for af

    3/26/26 12:00:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

    Woburn, Massachusetts--(Newsfile Corp. - March 16, 2026) - iSpecimen Inc. (NASDAQ:ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site network. Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected approximately 500 influenza swab samples over a period of several weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnarou

    3/16/26 7:47:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    SEC Filings

    View All

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.

    SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    3/27/26 1:03:56 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.

    SCHEDULE 13G/A - RxSight, Inc. (0001111485) (Subject)

    3/27/26 1:02:09 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/27/26 9:32:32 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SI-BONE Inc.

    SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)

    11/14/24 6:27:27 PM ET
    $SIBN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 5:46:12 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $AZTR
    $CLNN
    $FGEN
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care